Free Trial
NASDAQ:TBPH

Theravance Biopharma (TBPH) Stock Price, News & Analysis

Theravance Biopharma logo
$10.90 -0.26 (-2.33%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.90 -0.01 (-0.05%)
As of 08/1/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Theravance Biopharma Stock (NASDAQ:TBPH)

Key Stats

Today's Range
$10.88
$11.06
50-Day Range
$9.15
$11.65
52-Week Range
$7.44
$11.88
Volume
202,568 shs
Average Volume
154,642 shs
Market Capitalization
$545 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60
Consensus Rating
Moderate Buy

Company Overview

Theravance Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

TBPH MarketRank™: 

Theravance Biopharma scored higher than 36% of companies evaluated by MarketBeat, and ranked 714th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Theravance Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Theravance Biopharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Theravance Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Theravance Biopharma are expected to grow in the coming year, from ($1.09) to $0.35 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Theravance Biopharma is -9.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Theravance Biopharma is -9.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Theravance Biopharma has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Theravance Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    8.60% of the float of Theravance Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Theravance Biopharma has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Theravance Biopharma has recently decreased by 5.05%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Theravance Biopharma does not currently pay a dividend.

  • Dividend Growth

    Theravance Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.60% of the float of Theravance Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Theravance Biopharma has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Theravance Biopharma has recently decreased by 5.05%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Theravance Biopharma this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $491,800.00 in company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of Theravance Biopharma is held by insiders.

  • Percentage Held by Institutions

    99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Theravance Biopharma's insider trading history.
Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Stock News Headlines

Ex-Hedge Fund Manager Uncovers $100 Trillion Land Shift
Trump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline.
TBPH Theravance Biopharma, Inc. - Seeking Alpha
See More Headlines

TBPH Stock Analysis - Frequently Asked Questions

Theravance Biopharma's stock was trading at $9.41 at the beginning of 2025. Since then, TBPH stock has increased by 15.8% and is now trading at $10.90.

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.16. The biopharmaceutical company earned $15.39 million during the quarter, compared to analysts' expectations of $28.08 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 32.37% and a negative net margin of 89.38%.
Read the conference call transcript
.

Top institutional shareholders of Theravance Biopharma include Y Intercept Hong Kong Ltd (0.08%), Assenagon Asset Management S.A. (0.05%), R Squared Ltd (0.04%) and Ballentine Partners LLC (0.03%). Insiders that own company stock include Richard A Graham and Rhonda Farnum.
View institutional ownership trends
.

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/08/2025
Today
8/01/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TBPH
Previous Symbol
NASDAQ:TBPHV
CIK
1583107
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$9.00
Potential Upside/Downside
+52.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$56.42 million
Net Margins
-89.38%
Pretax Margin
-74.08%
Return on Equity
-32.37%
Return on Assets
-16.48%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.77
Quick Ratio
4.77

Sales & Book Value

Annual Sales
$64.38 million
Price / Sales
8.47
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.57 per share
Price / Book
3.05

Miscellaneous

Outstanding Shares
50,000,000
Free Float
46,551,000
Market Cap
$545 million
Optionable
Optionable
Beta
0.01

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:TBPH) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners